Upregulation of CD226 is found in peripheral blood CD8+T cells from PDAC patients after mFOLFIRINOX chemotherapy, which is associated with an elevated responsiveness of antigen-specific CD8+T cells to treatment with anti-TIGIT or anti-PD-1 mAbs, and has also been reported in the mouse tumor models [43]. Here, CD226 is linked to neoplasm.